Search

Your search keyword '"Calogero, D'Alessandria"' showing total 119 results

Search Constraints

Start Over You searched for: Author "Calogero, D'Alessandria" Remove constraint Author: "Calogero, D'Alessandria"
119 results on '"Calogero, D'Alessandria"'

Search Results

2. Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval

3. Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape

4. Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies

6. Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3

7. Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy

8. Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo

9. Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review

10. Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis

11. A Semi Rigid Novel Hydroxamate AMPED-Based Ligand for 89Zr PET Imaging

13. Stand der Technik in der Radiopharmazie

17. Data from Noninvasive In Vivo Imaging and Biologic Characterization of Thyroid Tumors by ImmunoPET Targeting of Galectin-3

19. Supplementary Materials and Figure legends S1-S7 from Preclinical Evaluation of the Hsp70 Peptide Tracer TPP-PEG24-DFO[89Zr] for Tumor-Specific PET/CT Imaging

20. Data from Preclinical Evaluation of the Hsp70 Peptide Tracer TPP-PEG24-DFO[89Zr] for Tumor-Specific PET/CT Imaging

21. Supplementary Figure S4A-C from Preclinical Evaluation of the Hsp70 Peptide Tracer TPP-PEG24-DFO[89Zr] for Tumor-Specific PET/CT Imaging

23. Supplementary Figure 5A-E from Preclinical Evaluation of the Hsp70 Peptide Tracer TPP-PEG24-DFO[89Zr] for Tumor-Specific PET/CT Imaging

26. Supplementary Figure S2A-F from Preclinical Evaluation of the Hsp70 Peptide Tracer TPP-PEG24-DFO[89Zr] for Tumor-Specific PET/CT Imaging

28. Data from Immuno-PET Imaging of Engineered Human T Cells in Tumors

29. Supplementary Figure S2 from Immuno-PET Imaging of Engineered Human T Cells in Tumors

30. The prognostic role of

31. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA

32. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T

33. Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

34. Room Temperature Al 18 F Labeling of 2‐Aminomethylpiperidine‐Based Chelators for PET Imaging

35. Detection Efficacy of (18)F‐rhPSMA‐7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment

36. Synthesis and Preclinical Evaluation of

37. Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?-An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer

38. Preclinical biodistribution and dosimetry and human biodistribution comparing

39. Radiolabelled cytokines for imaging chronic inflammation

41. Nomograms to predict outcomes after

42. Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study

43. Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo

44. Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (89Zr)-DFO- Galectin3-F(ab')2 mAb

45. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

46. Positive Predictive Value and Correct Detection Rate of

47. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using

48. Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive

49. The effect of attenuation map, scatter energy window width, and volume of interest on the calibration factor calculation in quantitative 177Lu SPECT imaging: Simulation and phantom study

50. Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer

Catalog

Books, media, physical & digital resources